Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease (LOCKCYST)

This study has been completed.
Sponsor:
Collaborator:
Ipsen
Information provided by (Responsible Party):
Dr Frederik Temmerman, Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier:
NCT01315795
First received: January 11, 2011
Last updated: July 7, 2014
Last verified: July 2014